quarta-feira, 7 de outubro de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 14, 2026

Warren Buffett Has Recommended This Surprising Investment for All Investors During Any Market Environment. Here's How It's Turned Out, According to History.

View original at nasdaq.com

Warren Buffett Has Recommended This Surprising Investment for All Investors During Any Market Environment. Here's How It's Turned Out, According to History…

Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

American business has done wonderfully over time and will continue to do so, though in unpredictable fits and starts, which underpins his confidence in S&P 500 index investing.
60% confidence

O que sabemos · a inteligência por trás desta página

Ao vivo do substrato

O que estamos a ver

Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave

Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.

A nossa leitura dos dados ›

Sinais que acompanhamos

Satellite-Terrestrial Network Integration Acceleration

Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

Padrões que observamos ›

Onde as fontes divergem

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Sinalizamos conflitos abertamente ›

Verificado recentemente

✓ Verificado com a fonte original

4,986

factos rastreados à sua fonte — e sinalizamos os que não se confirmam.

101 entidades acompanhadas4,986 factos verificados com a fonte5,351 documentos-fonte arquivados

Consulte estes dados → isubstrate.com